Drug combo for meningioma that keeps growing despite treatment
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a brain meningioma proven by pathology (tissue diagnosis from a surgery/biopsy)
- Your tumor must have one of the specific genetic markers (mutations or DNA copy number changes) checked by the trial’s central lab
- Your meningioma must be measurable on imaging (MRI preferred): clearly outlined spots with at least 10 mm on two dimensions
- The tumor must be progressing (or still present after surgery in a way that meets their rules), usually showing at least a 25% size increase within set scan time windows
- Depending on which medicine you’re assigned, you must meet safety labs/heart rules and have recovered enough from any prior radiation or chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
This trial tests a combination of two oral medications (vorasidenib and lomustine) for people whose brain tumor (glioma) has come back and has an IDH1 or IDH2 mutation. The goal is to see if this combination is safe and effective in halting or slowing tumor growth.
Hear when a new Intracranial Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.